- Home
- NRSN vs ICCC Comparison
NRSN vs ICCC Comparison
Compare NRSN & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- ICCC
- Stock Information
- Founded
- NRSN 2017
- ICCC 1982
- Country
- NRSN Israel
- ICCC United States
- Employees
- NRSN N/A
- ICCC N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- ICCC Health Care
- Exchange
- NRSN Nasdaq
- ICCC Nasdaq
- Market Cap
- NRSN 50.1M
- ICCC 60.1M
- IPO Year
- NRSN 2021
- ICCC 1987
- Fundamental
- Price
- NRSN $1.74
- ICCC $6.47
- Analyst Decision
- NRSN Buy
- ICCC
- Analyst Count
- NRSN 2
- ICCC 0
- Target Price
- NRSN $14.00
- ICCC N/A
- AVG Volume (30 Days)
- NRSN 225.6K
- ICCC 16.1K
- Earning Date
- NRSN 08-05-2025
- ICCC 08-14-2025
- Dividend Yield
- NRSN N/A
- ICCC N/A
- EPS Growth
- NRSN N/A
- ICCC N/A
- EPS
- NRSN N/A
- ICCC N/A
- Revenue
- NRSN N/A
- ICCC $27,302,766.00
- Revenue This Year
- NRSN N/A
- ICCC N/A
- Revenue Next Year
- NRSN N/A
- ICCC N/A
- P/E Ratio
- NRSN N/A
- ICCC N/A
- Revenue Growth
- NRSN N/A
- ICCC 28.29
- 52 Week Low
- NRSN $0.60
- ICCC $3.34
- 52 Week High
- NRSN $2.60
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- NRSN 39.25
- ICCC 47.68
- Support Level
- NRSN $1.69
- ICCC $6.25
- Resistance Level
- NRSN $2.09
- ICCC $7.30
- Average True Range (ATR)
- NRSN 0.15
- ICCC 0.32
- MACD
- NRSN -0.04
- ICCC -0.04
- Stochastic Oscillator
- NRSN 17.78
- ICCC 20.95
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.